Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Operating Leases (2022 - 2025)

Historic Operating Leases for Rani Therapeutics Holdings (RANI) over the last 4 years, with Q3 2025 value amounting to $3.0 million.

  • Rani Therapeutics Holdings' Operating Leases fell 2611.4% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 2611.4%. This contributed to the annual value of $3.6 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Rani Therapeutics Holdings' Operating Leases stood at $3.0 million, which was down 2611.4% from $3.2 million recorded in Q2 2025.
  • Rani Therapeutics Holdings' 5-year Operating Leases high stood at $4.7 million for Q1 2024, and its period low was $59000.0 during Q4 2022.
  • Over the past 4 years, Rani Therapeutics Holdings' median Operating Leases value was $1.7 million (recorded in 2022), while the average stood at $2.0 million.
  • As far as peak fluctuations go, Rani Therapeutics Holdings' Operating Leases tumbled by 4622.64% in 2023, and later surged by 224912.28% in 2024.
  • Quarter analysis of 4 years shows Rani Therapeutics Holdings' Operating Leases stood at $59000.0 in 2022, then soared by 189.83% to $171000.0 in 2023, then skyrocketed by 2026.9% to $3.6 million in 2024, then fell by 18.39% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $3.2 million for Q2 2025, and $3.4 million during Q1 2025.